2020 AAHAAAFP Feline Vaccination Guidelines

813_830_AAHA_AAFP Feline Vaccination Guidelines_3.8.2020.
qxp_FAB 03/08/2020 13:13 Page 813
Journal of Feline Medicine and Surgery (2020) 22, 813–830
SPECIAL ARticle
2020 AAHA/AAFP Feline

Vaccination Guidelines
Abstract: The guidelines are a consensus report on current recommendations for vaccination of cats
of any origin, authored by a Task Force of experts. The guidelines are published simultaneously in the
Journal of Feline Medicine and Surgery (volume 22, issue 9, pages 813–830, DOI: 10.1177/1098612X20941784) Amy ES Stone
DVM, PhD
and the Journal of the American Animal Hospital Association (volume 56, issue 4, pages 249–265, Chair of 2020 AAHA/AAFP
DOI: 10.5326/JAAHA-MS-7123). The guidelines assign approved feline vaccines to core (recommended Feline Vaccination
for all cats) and non-core (recommended based on an individualized risk–benefit assessment) categories. Guidelines Task Force*
Department of Small Animal
Practitioners can develop individualized vaccination protocols consisting of core vaccines and non-core Clinical Sciences, University
vaccines based on exposure and susceptibility risk as defined by the patient’s life stage, lifestyle, and place of Florida, Gainesville,
Florida, USA
of origin and by environmental and epidemiologic factors. An update on feline injection-site sarcomas
indicates that occurrence of this sequela remains infrequent and idiosyncratic. Staff education initiatives Gary O Brummet
DVM
should enable the veterinary practice team to be proficient in advising clients on proper vaccination practices
Veterinary Teaching Hospital,
and compliance. Vaccination is a component of a preventive healthcare plan. The vaccination visit should College of Veterinary
always include a thorough physical exam and client education dialog that gives the pet owner an Medicine, University of Illinois
at Urbana-Champaign,
understanding of how clinical staff assess disease risk and propose recommendations that help ensure Urbana, Illinois, USA
an enduring owner–pet relationship.
Ellen M Carozza
LVT
Keywords: Vaccination principles; vaccines; lifestyle; risk assessment; veterinarian; injection site; rabies; Nova Cat Clinic, Arlington,
leukemia; guidelines; maternally derived antibodies Virginia, USA
Philip H Kass
Abbreviations: DNA (deoxyribonucleic acid); FCV (feline calicivirus); FeLV (feline leukemia virus); DVM, MPVM, MS, PhD,
FHV-1 (feline herpesvirus type 1); FIP (feline infectious peritonitis); FISS (feline injection-site sarcoma); DACVPM (Specialty
FPV (feline panleukopenia virus); Ig (immunoglobulin); IM (intramuscular); MDA (maternally derived in Epidemiology)
Department of Population
antibodies); SC (subcutaneous); WSAVA (World Small Animal Veterinary Association) Health and Reproduction,
School of Veterinary
Medicine, University
These guidelines were prepared by a Task Force Introduction of California, Davis,
Davis, California, USA
of experts convened by the American Animal
Hospital Association (AAHA) and the American As a medically essential and cost-effective Ernest P Petersen
Association of Feline Practitioners (AAFP) and method of infectious disease control, vaccina- DVM, PhD, DABVP (Feline)
Animal Hospital of Parkland,
were subjected to a formal peer-review process. tion continues to be a mainstay of feline Tacoma, Washington, USA
This document is intended as a guideline only, not practice and a critical component of an indi-
Jane Sykes
an AAHA or AAFP standard of care. These guide- vidualized preventive healthcare plan. These BVSc (Hons), PhD,
lines and recommendations should not be con- guidelines provide the most current informa- DACVIM, MBA
strued as dictating an exclusive protocol, course tion and recommendations for feline vaccina- University of California,
Davis, Davis, California, USA
of treatment, or procedure. Variations in practice tion as determined by a Task Force of experts
may be warranted based on the needs of the indi- in feline practice. The recommendations are Mark E Westman
BVSc (Hons), PhD,
vidual patient, resources, and limitations unique evidence-guided, based on current peer- MANZCVS (Animal
to each individual practice setting. Evidence- reviewed literature and data, and complement- Welfare), GradCert Ed Stud
based support for specific recommendations has ed by clinical insights collectively derived from (Higher Ed))
Sydney School of Veterinary
been cited whenever possible and appropriate. decades of experience. The guidelines update Science, University of
Other recommendations are based on practical the “2013 AAFP Feline Vaccination Advisory Sydney, Sydney,
New South Wales, Australia
clinical experience and a consensus of expert opin- Panel Report” and utilize similar recommenda-
ion. Further research is needed to document some tions from the 2016 “WSAVA [World Small *Corresponding author:
stonea@vetmed.ufl.edu
of these recommendations. Because each case is Animal Veterinary Association] Guidelines for
different, veterinarians must base their decisions on
the best available scientific evidence in conjunction
with their own knowledge and experience.
DOI: 10.1177/1098612X20941784
© 2020 by American Animal Hospital Association, American Association
of Feline Practitioners and International Society of Feline Medicine
JFMS CLINICAL PRACTICE 813
813_830_AAHA_AAFP Feline Vaccination Guidelines_3.8.2020.qxp_FAB 03/08/2020 13:13 Page 814
S P E C I A L A R t i c l e / 2020 AAHA/AAFP feline vaccination guidelines
the Vaccination of Dogs and Cats”.1,2 Both of Vaccination principles

these previously published resources should
still be considered relevant and actionable Active immunization, achieved through prop-
complements to the 2020 guidelines. er vaccination, plays a critical role in the con-
The guidelines continue the established trol of infectious diseases, both for individual
approach of considering inclusion of core cats and for the cat population as a whole.
(recommended for all cats) and non-core Some vaccines also reduce the potential for
(recommended based on an individualized spread of zoonotic infections to humans (e.g.,
risk–benefit assessment) vaccines in an indi- rabies). The benefits of routine, widespread
vidualized protocol. As explained in the vaccination are clear: the incidence of serious
guidelines, a patient-specific vaccination plan disease caused by pathogenic organisms, such
should consider environmental risk factors as feline panleukopenia virus (FPV), can be
and life stage and lifestyle factors that deter- reduced dramatically when widespread vacci-
mine the likelihood of infectious disease expo- nation is practiced. However, the quality of
sure and susceptibility. For example, not all vaccine-induced immunity is influenced by
feline patients originate from a home environ- the patient’s environment, the characteristics
ment, and conversely, most cats described as of the vaccine, the pathogen, and the patient’s
“indoor only” might find themselves periodi- immune competence. Accurate prediction of
cally exposed to other cats. The guidelines the outcome of vaccination or the likelihood
discuss other presentation scenarios that can of exposure to a pathogen is impossible.
potentially affect a risk–benefit assessment
Kittens may Therefore, it is important that veterinarians
and include updates on feline injection-site be susceptible inform cat owners that vaccination is not a
sarcomas (FISSs) and other vaccination- guarantee of protection.
related reactions. to infectious In general, kittens are more susceptible to
A key component of the guidelines are com- diseases infection and disease than adults. Thus, they
prehensive, easy-to-reference tables listing represent a primary target population for
approved core and non-core feline vaccines at about immunization. As part of a routine wellness
and the relevant considerations for their program, the vaccination needs of all cats
use. The guidelines are complemented by 1 month of age, should be assessed annually, in conjunction
an online resource center at aaha.org/ perhaps as with a comprehensive physical examination,
felinevaccination and supplemental materials modifying vaccination and other control
at catvets.com/vaccination. The online much as recommendations as necessary based on the
resources include frequently asked questions current risk (see “Vaccination risk–benefit
about vaccination that clinicians and pet own- 2 weeks earlier assessment”).
ers raise as well as a vaccine protocol calcula- than puppies. Kittens born to immune queens lack signifi-
tor that uses a cat’s life stage and lifestyle cant transplacentally acquired antibodies4 and
information to suggest an appropriate, indi- instead absorb specific maternally derived
vidualized vaccination protocol. antibodies (MDA) through colostrum, which
The guidelines discuss in some detail the provides important protection during early
importance of staff and client education in life. Most absorption occurs within 24 hours
implementing vaccination protocols and rec- of birth. However, this MDA also interferes
ommendations for feline patients. This with active immunization. Serum MDA
emphasis is noteworthy in view of the fact inhibits immunoglobulin (Ig)G production
that many pet owners, especially cat owners, within the neonate through negative feedback
associate professional veterinary care primar- mechanisms. It also neutralizes vaccine anti-
ily with two events, vaccination and treatment gens and prevents them from stimulating an
of acute conditions.3 Thus, a healthcare visit immune response. MDA then declines at a
for the purposes of vaccination becomes an variable rate. Maternally derived IgG in kit-
opportunity to more broadly discuss an tens in one study was lowest at around 3–4
overall preventive healthcare strategy with weeks of age, and serum IgG and IgA
the pet owner. Implicit in this approach is increased dramatically at 5–7 weeks of age.4
an explanation of how the clinician These results suggested that kittens may
considers life stage, lifestyle, patient be susceptible to infectious diseases at
health status, environmental, and epi- about 1 month of age, perhaps as much
demiologic factors in making vaccina- as 2 weeks earlier than puppies.
tion recommendations. The vaccination ONLINE RESOURCES Nevertheless, it is critical to recognize
event then occurs in the context of a The guidelines are complemented that there is considerable individual
practitioner–client discussion on how by an online resource center at variation in the rate of decline of MDA,
preventive healthcare forms the basis for aaha.org/felinevaccination and some kittens maintain high concen-
and supplemental materials at
the pet owner to maintain a long, reward- catvets.com/vaccination
trations for months.5 The persistence of
ing relationship with the animal in his MDA is one of the most common reasons
or her care. for vaccine failure. The amount of MDA in a
814 JFMS CLINICAL PRACTICE

kitten at any one time point cannot be predict- This means that the series must be extended 3–4
ed because it varies depending on the titer of weeks beyond the period in which the decline in
the dam and the amount of colostrum ingest- MDA occurs, with the final vaccination dose being
ed after birth. As a result, a series of vaccinations a booster. In the past, it was recommended that
is administered to kittens every 2–4 weeks through revaccination be performed 1 year after the
16–18 weeks of age in order to increase the chance initial kitten series, and then for most vaccines
that successful immunization will occur soon after every 3 years thereafter. However, owing to
the decline of MDA to sufficiently low titers. The studies that suggest up to one-third of kittens
series is started no sooner than 4 weeks of age, may fail to respond to a final core vaccine at
because neonates are more likely to develop 16 weeks and may have blocking MDA at
vaccine organism-associated disease and may 20 weeks, the WSAVA recommends that the
not respond well to vaccination. During 1 year vaccine (feline viral rhinotracheitis–
administration of the series, a window exists calicivirus–panleukopenia only) be replaced
when MDA concentrations are high enough to with revaccination at 6 months of age.2,6,7
interfere with immunization but are not suffi- In this update, this Task Force has adopted the
cient to prevent natural infection. This window same recommendation of revaccination against
of susceptibility can be minimized by decreas- FPV, feline herpesvirus type 1 (FHV-1), and feline
ing the interval between vaccinations in the calicivirus (FCV) at 6 months of age to potentially
series, although use of intervals less than reduce the window of susceptibility in kittens with
2 weeks can interfere with successful MDA toward the end of the kitten series (16–18
immunization, especially with attenuated live weeks). The Task Force recognizes that this
vaccines. means an additional visit will still be neces-
Once vaccination has been successfully sary for administration of the annual feline
achieved after the decline of MDA, it is gener- leukemia virus (FeLV) and rabies vaccinations
ally recommended that a booster vaccine be in young cats.
given 3–4 weeks later (this is especially The risk of infection and disease varies with
important for inactivated vaccines, although a factors such as the age and health of the cat,
boostering effect will also occur following magnitude of exposure to the infectious agent,
revaccination with attenuated live vaccines). the pathogenicity of the agent, and the
Table 1 Types of feline vaccines and their attributes
Attributes Inactivated Attenuated live Recombinant
Vaccines, Examples FPV, FHV-1, FCV, FeLV, FPV, FHV-1, FCV, FIP, Rabies, FeLV
rabies, Chlamydia Chlamydia, Bordetella
including those
Replication after Does not replicate May replicate locally and at Limited replication, which
from different administration sites beyond the inoculation is then aborted (for
site canarypox-vectored
vaccines)
manufacturers
Initial vaccination With the exception of One dose may be sufficient; Rabies: One dose is
that are in the absence of MDA rabies, two initial doses however, where the likelihood required. Protective
required, 3–4 weeks apart of infection is high, two initial immunity is expected to
licensed to doses are recommended, develop by 28 days
Protective immunity is 3 weeks apart
protect against expected within 7–10 days FeLV: Two initial doses are
of the second dose. For Protective immunity is required, 3–4 weeks apart.
rabies, only one dose is expected within 7–10 days Protective immunity is
the same required, and protection is of the second dose expected within 7–10 days
expected within 28 days of the second dose
pathogen,
Route(s) of Parenteral (SC, IM) Parenteral (SC, IM): FPV, Parenteral (SC)
should not be administration as FHV-1, FCV, Chlamydia
stipulated by the
assumed as manufacturer Mucosal (intranasal): FPV,
FHV-1, FCV, FIP, Bordetella
equivalent.
Adjuvanted Yes, with some exceptions Not required Some products contain
adjuvant; canarypox-
vectored products are
non-adjuvanted
Vaccine organism- Not possible Possible, but uncommon, Not possible

induced disease following intranasal
administration of respiratory
virus vaccines or oral
exposure to leaked parenteral
vaccine on haircoat

Because vaccine-induced protection is variable tion of rabies, two initial doses of vaccine
3–4 weeks apart in the absence of MDA are
and not absolute, vaccination should not be used absolutely essential to produce an effective
immune response, and if more than 6 weeks
as the only form of protection. elapses between these doses, it is recommend-
ed in other guidelines reports that the series
be repeated.2,8 Full protection may not devel-
vaccination history of the cat. Some of the op until 2–3 weeks after the last dose.
factors that impact an individual animal’s abil- Inactivated vaccines are generally considered
ity to respond to vaccination include interfer- safer than attenuated live vaccines for use
ence from MDA, congenital or acquired during pregnancy and in immunosuppressed
immunodeficiency, concurrent disease, inade- animals, although systemic allergic reactions
quate nutrition, chronic stress, and very young could still jeopardize pregnancy.
or old age. Some vaccines (e.g., those for FPV) < Attenuated live vaccines (modified live
induce a stronger protective response than vaccines) contain microorganisms that are
others (e.g., those for FHV-1). Because vaccine- artificially manipulated so as to reduce their
induced protection is variable and not abso- virulence or are field strains of low virulence.
lute, vaccination should not be used as the Repeated passage through cell culture is the
only form of protection, and other control most common means of attenuation. Because
measures, such as those that reduce exposure organisms in attenuated live vaccines replicate
to infectious agents, should also be employed. in the host, they stimulate an immune response
that more closely mimics protection from
Types of feline vaccines natural infection. There is generally a more
Vaccines, including those from different rapid onset of immunity than with inactivated
manufacturers that are licensed to protect vaccines, and, in the absence of MDA, only one
against the same pathogen, should not be dose of vaccine may be sufficient to provide
assumed as equivalent. Differences in pro- protection. Partial immunity after vaccination
cesses and technology used to produce vac- with a single dose of attenuated live FPV
cines, as well as additives such as adjuvants, vaccines can occur within hours.9–11 In
and vaccine route of administration influence addition, live vaccine organisms that are shed
efficacy, safety, and duration of immunity. can immunize other animals in a population.
Vaccines may be inactivated, attenuated live, However, the potential for vaccine organism-
or recombinant (Table 1). All veterinary vac- induced disease exists. This is most likely to
cines, before licensing, are assessed for effica- occur in immunosuppressed animals, such as
cy, safety, potency, and purity. Vaccine efficacy neonates that are younger than 4 weeks old.
is often expressed as preventable fraction, In addition, use of attenuated live vaccines
defined as the proportion of vaccinated is more likely to result in the generation of
animals that do not develop a disease after false-positive results as indicated by diagnostic
challenge (so-called sterilizing immunity, e.g., tests that are designed to detect the target
FPV, FeLV, and rabies vaccines), compared pathogen (antigen or nucleic acid). With
with unvaccinated animals that do develop prolonged shedding of live vaccine organisms,
the disease. It can also be expressed as mitigat- this can be a problem for weeks after
able fraction (proportion with reduction in vaccination. All bacterial and viral vaccines
severity of clinical signs, e.g., FHV-1 and FCV licensed for intranasal administration in cats
vaccines). Other claims include reduction of are attenuated live, as are a number of
pathogen shedding, prevention of a specific parenteral vaccines.
clinical sign, or prevention of mortality. The < Recombinant vaccines are created through
level or degree of protection claim can there- manipulation of the deoxyribonucleic acid
fore be limited. (DNA) of a pathogen in the laboratory, with
< Inactivated vaccines are vaccines in which reduction in pathogen virulence. Types of
the target pathogen is “killed” and therefore recombinant vaccines include subunit,
unable to replicate in the host. Although these deletion mutant, vectored, and DNA vaccines.
vaccines are unable to revert to virulence, they Currently, the only available recombinant
often contain adjuvants and other excipient vaccines for cats in North America are vectored
proteins to promote an adequate immune vaccines, which use a recombinant canarypox
response, which have been implicated in virus as a vector. In these vaccines, DNA of the
acute and delayed adverse reactions in cats. pathogen that encodes for an immunogenic
Inactivated vaccines produce weaker immune antigen is incorporated into the canarypox
responses of shorter duration when compared genome, which then undergoes aborted
with attenuated live vaccines, and more (limited) replication in the host with expression
frequent booster immunizations may be of the immunogen, in turn inciting a protective
required (generally annually). With the excep- immune response. Compared with inactivated

Table 2 Core vaccines for pet cats (continued on page 818)
<16 Weeks of >16 Weeks of

age first dose age first dose Clinically relevant comments
administered: administered: Revaccination for administration
PARENTERAL No earlier than 6 One or two doses Consider at 6 months* of age < Vaccination of pregnant queens
weeks of age and of a combination rather than 1 year of age to and kittens <4 weeks of age should
Attenuated live then q 3–4 weeks vaccine decrease the potential be avoided because of the theoretical concern
until 16–20 weeks window of susceptibility if for cerebellar hypoplasia15,16
of age the kitten had MDA at the < Because of the theoretical risk of clinical
last kitten booster2,6,7 (see signs due to residual virulence of the
comments in text) attenuated virus in an immunocompromised
patient, consider avoiding in cats with
Revaccinate q 3 years retrovirus infections17,18
thereafter2 < Provides cross-protection to canine
parvovirus-219,20
*Note: This means an < Considered by many clinicians to be their
additional visit for the first choice for protection against FPV,
annual FeLV and rabies especially in high-risk cats owing
revaccination in young cats to more rapid protective response than
inactivated vaccines16,21,22
< For cats going into boarding or other high-
exposure, stressful situations, revaccination
7–10 days prior to boarding may be warranted,
particularly if the cat has not been vaccinated
in the preceding year
< Cats residing in a high-risk environment
FPV + FHV-1 + FCV
when presented for initial vaccination may

benefit from administration of two doses of
a combination vaccine 2–4 weeks apart
PARENTERAL No earlier than 6 Two doses q 3–4 Consider at 6 months* of age < Likely safer for use in pregnant cats and
weeks of age and weeks apart rather than 1 year of age those with retrovirus infections
Inactivated then q 3–4 weeks to decrease the potential < Administration should not be avoided in
until 16–20 weeks window of susceptibility if cats with retroviral infection because they can
of age the kitten had MDA at the develop more severe clinical signs if exposed
last kitten booster2,6,7 (see to FPV and upper respiratory infections17
comments in text) < Provides cross-protection to canine
parvovirus-219,20
Revaccinate q 3 years < Dual-strain calicivirus vaccines may
thereafter2 provide broader cross-protection23
*Note: This means an < For cats going into boarding or other high-
additional visit for the exposure, stressful situations, revaccination
annual FeLV and rabies 7–10 days prior to boarding may be warranted,
revaccination in young cats particularly if the cat has not been vaccinated
INTRANASAL No earlier than 6 One dose and Revaccinate annually < Provides faster protection, which
weeks of age and then yearly is especially relevant in high-risk populations
Attenuated live then q 3–4 weeks thereafter Revaccination can be helpful and with kittens against respiratory disease24
until 16–20 weeks in mitigating upper < Consider vaccination simultaneously with
of age respiratory infections in parenteral FPV25
stressful/boarding situations < Might cause transient clinical signs
of respiratory disease
INTRANASAL Start at 4–6 weeks One dose and Revaccinate annually < No protection against FPV
of age and then then yearly < Provides faster protection, which
Attenuated live q 3–4 weeks until thereafter Revaccination can be helpful is especially relevant in high-risk populations
16–20 weeks of in mitigating upper and with kittens against respiratory disease24
age respiratory infections in < Might cause transient clinical signs
stressful/boarding situations of respiratory disease
FHV-1 + FCV
< Although mucosal vaccines are not

generally considered impacted by MDA
interference, the Task Force feels the regimen
for <16-week-old kittens is ideal to prevent
morbidity from FHV-1 and FCV in very young
kittens

Table 2 Core vaccines for pet cats (continued from page 817)

age first dose age first dose Clinically relevant comments
administered: administered: Revaccination for administration
PARENTERAL Two doses 3–4 Two doses 3–4 Revaccinate 12 months after < Considered a core vaccine for kittens
weeks apart weeks apart the last dose in the series, and young adult cats <1 year of age owing
Recombinant beginning as then annually for individual to age-related susceptibility
early as 8 weeks cats at high risk of regular < Considered a non-core vaccine for low-risk
(live canarypox of age exposure through adult cats (no potential exposure to other FeLV+
vector) encountering FeLV+ cats and cats or cats of unknown FeLV status)
cats of unknown FeLV status < Test to establish FeLV antigen status prior
either indoors or outdoors13 to vaccination (see text for comments)
< There is conflicting evidence in the literature
regarding efficacy and safety when comparing
recombinant and inactivated vaccines (see text
for comments)12–14,28–30
< The Task Force acknowledges that if an
FPV–FHV-1–FCV vaccine is administered at
6 months of age, an additional visit will be
required to facilitate vaccinating 12 months after
the last FeLV vaccine in the kitten series
PARENTERAL Two doses 3–4 Two doses 3–4 Revaccinate at 12 months < Considered a core vaccine for kittens
weeks apart weeks apart after the last dose in the and young adult cats <1 year of age owing
Inactivated beginning as series and then consider to age-related susceptibility
FeLV
early as 8 weeks revaccination:* < Considered a non-core vaccine for low-risk

of age < Annually for individual cats adult cats (no potential exposure to other FeLV+
with regular exposure through cats or cats of unknown FeLV status)
living with FeLV+ cats and < Test to establish FeLV antigen status prior
cats of unknown FeLV status to vaccination (see text for comments)
either indoors or outdoors < There is conflicting evidence in the literature
< Every 2–3 years, where regarding efficacy and safety when comparing
product licensure allows, for recombinant and inactivated vaccines (see text
individual adult cats less likely for comments)12–14,28–30
to have regular exposure to < The Task Force acknowledges that if an
FeLV+ cats26,27* FPV–FHV-1–FCV vaccine is administered at
6 months of age, an additional visit will be
*At-risk (fighting, outdoor required to facilitate vaccinating 12 months after
lifestyle, etc.) adult cats should the last FeLV vaccine in the kitten series
continue to be vaccinated
against FeLV annually. The
consensus of the Task Force is
revaccination every 2 years in
periodic exposure situations in
mature cats. Where vaccines
with a 3-year duration of
immunity are available, their
use can be considered
Administration instructions Clinically relevant comments for administration
PARENTERAL Follow vaccine label instructions < There is conflicting evidence in the literature regarding safety when
and local laws comparing recombinant and inactivated vaccines (see text for comments)12,30
Recombinant < Where rabies vaccination is required, the frequency of vaccination may differ
based on local statutes or requirements. Veterinarians should be familiar with,
(live canarypox and adhere to, local requirements
Rabies
vector)
PARENTERAL Follow vaccine label instructions < There is conflicting evidence in the literature regarding safety when
and local laws comparing recombinant and inactivated vaccines (see text for comments)12,30
Inactivated < Where rabies vaccination is required, the frequency of vaccination may differ
based on local statutes or requirements. Veterinarians should be familiar with,
and adhere to, local requirements
< When local laws/regulations permit, the Task Force recommends a 3-year
vaccination interval using a 3-year labeled vaccine
vaccines, canarypox vectors offer a more rapid

Core vaccines canarypox FeLV vaccine may not be as robust
onset of immunity and may be more effective are for all cats as that induced by whole inactivated FeLV
in the face of persistent MDA. Canarypox- vaccines,13 which might produce sterilizing
vectored vaccines also do not require adjuvant with an unknown immunity.14 However, moderate to severe
and have been associated with a reduced risk immunosuppression may have impacted the
vaccination
of injection-site sarcomas in cats.12 However, results, so further studies are required to
one study suggested that the degree of history. determine whether a clinically important
protection induced by the recombinant difference exists.

3Table 3 Core vaccines for shelter-housed cats

age first dose age first dose
administered: administered: Clinically relevant comments for administration
PARENTERAL Single dose at For adults, single < Vaccination of pregnant queens and kittens <4 weeks of age
intake or where dose at intake or should be avoided because of the theoretical concern for cerebellar
Attenuated live possible at least where possible hypoplasia15,16
1 week before at least 1 week < Because of the theoretical risk of clinical signs due to residual virulence
shelter entry; in before shelter of the attenuated virus in an immunocompromised patient, consider
kittens, the first entry avoiding in cats with retrovirus infections17,18
dose no earlier < Provides cross-protection to canine parvovirus19,20
FPV + FHV-1 + FCV
than 4 weeks, and Second dose < Considered by many clinicians to be their first choice for protection
then q 2 weeks 2 weeks later against FPV, owing to more rapid protective response than inactivated
until 16–20 weeks vaccines16,21,22
of age
PARENTERAL
Not recommended owing to delayed protective response specifically for FPV (see comments in text)5,9–11
Inactivated
INTRANASAL Not recommended in shelters owing < Do not vaccinate any earlier than 4 weeks of age because of the
to less-than-optimal protection concern for cerebellar hypoplasia15,16
Attenuated live against panleukopenia31 < Shelters should be aware that postvaccinal clinical signs associated
with the use of intranasal vaccines could be confused with those caused
by natural infections
< Provides faster protection, which is especially relevant in high-risk
populations and with kittens against respiratory disease24
< Consider vaccination simultaneously with parenteral FPV
< Might cause transient clinical signs of respiratory disease
INTRANASAL Single dose at Single dose at < Do not vaccinate any earlier than 4 weeks of age because of the concern
FHV-1 + FCV
intake or where intake or where for cerebellar hypoplasia15,16

Attenuated live possible at least possible at least < Shelters should be aware that postvaccinal clinical signs associated
1 week before 1 week before with the use of intranasal vaccines could be confused with those caused
shelter entry; in shelter entry by natural infections
kittens, administer < Provides faster protection, which is especially relevant in high-risk
no earlier than populations and with kittens against respiratory disease24
4 weeks < Might cause transient clinical signs of respiratory disease
PARENTERAL Two doses 3–4 Two doses 3–4 < Optional in individually housed cats but shelters should consider the
weeks apart weeks apart benefits of vaccinating more cats against FeLV
Recombinant beginning as early < Strongly recommended in group-housed cats
as 8 weeks of age < Recommend testing to establish FeLV antigen status prior to vaccination
(live canarypox (see text for comments)
vector) < There is conflicting evidence in the literature regarding efficacy and safety
when comparing recombinant and inactivated vaccines (see text for
comments)12–14,28–30
FeLV
PARENTERAL Two doses Two doses 3–4 < Optional in individually housed cats but shelters should consider the
3–4 weeks apart weeks apart benefits of vaccinating more cats against FeLV
Inactivated beginning < Strongly recommended in group-housed cats
as early as < Recommend testing to establish FeLV antigen status prior to vaccination
8 weeks of age (see text for comments)
< There is conflicting evidence in the literature regarding efficacy and safety
comments)12–14,28–30
Administration instructions Clinically relevant comments for administration
PARENTERAL Follow vaccine label instructions < Necessary for all cats where legally allowed/mandated or in an endemic region
and local laws < The authority to administer rabies vaccine to shelter-housed cats is often
Recombinant stipulated by state or local law and may not be at the discretion of shelter
personnel
(live canarypox < In states/provinces where rabies vaccination may not be mandated,
vector) shelters should consider the benefits of vaccinating more cats against rabies
Rabies
comments)12,30
PARENTERAL Follow vaccine label instructions < Necessary for all cats where legally allowed/mandated or in an endemic region
and local laws < The authority to administer rabies vaccine to shelter-housed cats is often
Inactivated stipulated by state or local law and may not be at the discretion of shelter
personnel
< In states/provinces where rabies vaccination may not be mandated,
shelters should consider the benefits of vaccinating more cats against rabies
comments)12,30

3Table 4 Non-core vaccines for pet cats
Clinically relevant comments for

Non-core
Administration instructions administration
vaccines are
INTRANASAL For frequency and interval, follow < Not routinely used in pet cats
Bordetella
label instructions < Provides incomplete protection optional

Attenuated live < Use as part of a control program in
a multi-cat household where infection vaccines that
is confirmed
< Never administer parenterally should be
PARENTERAL For frequency and interval, follow < Provides incomplete protection
label instructions < Use as part of a control program in a multi-
considered
Inactivated cat household where infection is confirmed
< Vaccination may be associated with a higher
in the light of
Chlamydia
risk of adverse effects (lethargy, limb soreness,

anorexia)32 exposure risk.
PARENTERAL For frequency and interval, follow < Provides incomplete protection
label instructions < Use as part of a control program in a multi-
Attenuated live cat household where infection is confirmed
< Vaccination may be associated with a higher
risk of adverse effects (lethargy, limb soreness,
anorexia)32
To facilitate vaccine selection, vaccines for significance or that respond readily to

dogs and cats have been divided into core treatment; vaccines for which evidence of
vaccines, non-core vaccines, and those gener- efficacy in the field is minimal; or vaccines that
ally not recommended. may produce a relatively higher incidence of
< Core vaccines are for all cats with an adverse events with limited benefit. The Task
unknown vaccination history. The targeted Force lists the feline infectious peritonitis (FIP)
diseases cause significant morbidity and vaccine as not generally recommended (Table
mortality and are widely distributed. In 5). This vaccine is labeled for administration
general, vaccination for core diseases results in from 16 weeks of age, whereas many kittens
good protection. The Task Force recommends become infected with coronaviruses well
vaccines for FHV-1, FCV, FPV, rabies, and before this age. It also contains a serotype II
FeLV (cats younger than 1 year old) as core strain of FIP virus. Serotype I FIP virus strains
vaccines (Table 2, pet cats; Table 3, shelter- predominate in the field and do not have cross-
housed cats). reactive neutralizing epitopes with serotype II
< Non-core vaccines are optional vaccines strains. Therefore, as noted in the previous
that should be considered in the light of iteration of these guidelines,1,33 there remains
exposure risk; that is, based on geographic insufficient evidence that this vaccine induces
distribution and the lifestyle of the cat (Table clinically relevant protection in the field.
4). Optional or non-core vaccines for cats The decision to vaccinate, even with core
include FeLV (for cats older than 1 year), vaccines, should be based on a risk–benefit
Chlamydia felis, and Bordetella bronchiseptica assessment for each cat and for each vaccine
vaccines. antigen. Benefits of vaccination should be
< The not generally recommended category balanced against the risk of adverse events,
of vaccines pertains to diseases of low clinical likelihood of exposure, and disease severity.
Table 5 Not generally recommended vaccines for pet cats
The Task Force Administration instructions Clinically relevant comments for administration
lists the INTRANASAL For frequency and interval, < Not generally recommended at this time because
follow label instructions its uncertain ability to uniformly prevent disease in
FIP vaccine Attenuated live North American cat populations does not justify its
routine use
as not generally < Only coronavirus seronegative cats have the
potential to be protected, and most cats are
FIP
recommended. seropositive before the age of recommended

vaccination
< Vaccine virus (serotype II) differs from the serotype
(I) that predominantly causes clinical disease
< The benefits and risks of vaccination remain
unclear (see comments in text)

Every effort should be made to ensure that and instead absorb specific MDA through
cats are healthy before vaccination. However, colostrum,4 which provides important protec-
concurrent illness (including retroviral infection during early life. Once MDA have waned,
tions) does not necessarily preclude vaccina- however, kittens become susceptible to infec-
tion.34 The 2020 AAFP Feline Retrovirus tion. Most infectious diseases are more
Testing and Management Guidelines state prevalent in kittens than adults, and therefore,
that vaccines should not be avoided in cats kittens (in particular, those younger than
with retroviral infection because they can 6 months old) represent a principal primary
develop more severe clinical disease related to target population for vaccination. Conversely,
FPV and upper respiratory tract infections adult cats generally have a more robust adap-
after natural exposure compared with tive immune response when challenged
uninfected cats.34 (assuming they are healthy and not immuno-
compromised), whether due to previous
Potential therapeutic benefits natural exposure or vaccination, and age-
of vaccination related resistance to challenge is particularly a
Active immunization can enhance non-specific A balancing act feature of FeLV infection.26 Consequently, vac-
immunity, leading to reduction in disease There is always a cination of mature cats is generally considered
caused by non-target pathogens. One study balance to be struck less critical than vaccination of kittens. The
showed that vaccination of cats with an when considering presence of concurrent disease or stress
intranasal FHV-1–FCV vaccine was associated risks associated with causing immunosuppression should also be a
with reduction in clinical signs following chal- vaccination and consideration prior to vaccination because
lenge with B bronchiseptica.24 More studies are benefits of this may affect an animal’s susceptibility to
needed to assess the non-target effects of vaccination for the infection and response to vaccination.
different vaccine types. There is also interest individual patient:
in whether vaccines might provide therapeu- < A decision TO Patient’s environment
tic benefits in cats already infected with target VACCINATE might Population density and opportunity for expo-
pathogens. Improvement in chronic upper involve a young cat sure to infectious agents are two critical issues
respiratory tract signs that were previously residing in a multi-cat that should form part of the risk–benefit
refractory to other treatments was document- household with assessment. In general, cats and kittens living
ed in 13 cats vaccinated with an intranasal outdoor access, in larger multi-cat households and environ-
FHV-1–FCV vaccine.35 Most vaccines, however, living in an area ments (e.g., boarding, breeding, foster, or shel-
provide no therapeutic benefit, as clearly with a known high ter facilities) have a higher risk of infection
documented for FeLV vaccines.36 prevalence of the than cats living in one- or two-cat households.
pathogen being In addition to the possible presence of infected
Vaccination risk–benefit vaccinated against. animals acting as reservoirs for infection in
assessment < A decision NOT multi-cat households, the immunosuppressive
TO VACCINATE might effects of stress associated with high-density
The Task Force supports the WSAVA’s involve a senior or feline housing may result in reactivation of
recommendation that veterinarians should geriatric cat residing some infections as well as increased suscepti-
vaccinate every animal with core vaccines and in a single-cat bility to new infections. The introduction of
give non-core vaccines no more frequently household with no new cats into multi-cat households also
than is deemed necessary.2 The decision outdoor access, and increases the risk of infectious disease not only
whether or not to administer a vaccine to a a vaccine that has to the cat entering the household but also to
cat, and how frequently, relies on an individu- poor efficacy against the whole group because of possible direct
al case-by-case assessment by the veterinari- a pathogen with low exposure to new infectious agents.
an. This involves consideration of the animal, virulence or limited When assessing the opportunity for expo-
the animal’s environment, and the pathogen local prevalence. sure to a given pathogen for an individual cat,
in question. Additionally, risk–benefit assess- the lifestyle of the cat and other cats in the
ments should consider the safety of the same household needs to be considered. It is
vaccine, other adverse effects of vaccination critical to determine whether the cat is indoor-
(e.g., the effect of feline immunodeficiency only or has outdoor access (including super-
virus vaccination on in-clinic diagnostic test vised outdoor visits on a harness, or boarding)
kits), and the efficacy of the vaccine. The result because cats with outdoor access may be at
of this assessment should be an individual- increased risk of pathogen exposure. Indoor-
ized, evidence-guided recommendation to only cats, however, may still be determined to
vaccinate or not to vaccinate. be at risk of exposure to pathogens, either
from other cats in the household (i.e., subclin-
Patient’s characteristics ically infected or carrier cats), or by fomite
Age is an important factor in assessing an transmission of pathogens brought in from
individual’s risk profile. In contrast to pup- outside on the owner’s body, clothing, or
pies, kittens born to immune queens appear shoes. Indoor-only cats may also be exposed
to lack transplacentally acquired antibodies to infectious agents when brought to a veteri-

nary clinic for a wellness examination. In 3Table 6

theory, strictly indoor cats may be more sus- Risk assessment variables determining an
ceptible to developing some infectious dis- individualized vaccination plan
eases (such as FPV and FCV infection) than Risk factors Considerations
cats with outdoor access because they may Age and life stage Susceptibility, MDA, activity level, reproductive status
not receive “natural boosting of immunity”
Health status Concurrent disease, nutritional status, level of parasitism
that occurs with natural exposure.1
The geographic distribution of infectious Agent exposure Geographic prevalence, cat lifestyle, housing
agents may also result in different risks of
History Adverse vaccine events, response to vaccination by littermates,
exposure (e.g., rabies), and therefore, ques- previous disease
tions regarding future travel should be includ-
Immunodeficiency Congenital or acquired (including chronic stress)
ed in determining the risk of exposure to
specific infectious agents.
Infectious agents the type and schedule of vaccination for that

The likelihood of infection and disease is individual cat (Table 6). As with lifestyle
influenced by pathogen factors such as viru- changes, changes in health status must be
lence, strain variation, and challenge dose evaluated at least yearly.1
(i.e., how many infectious units of exposure). The population density, along with the
The need for vaccination is greatest against opportunity for exposure to other cats, is a
pathogens with high virulence, such as FPV, major factor in determining the need for
and pathogens that cause widespread mor-
One vaccination. Larger multi-cat households are
bidity, such as FHV-1. vaccination likely to have a greater risk of infection and
disease than households of one or two cats.
Creating an individualized, plan or The introduction of new cats and the social
lifestyle-based vaccination plan protocol dynamics of the group may also cause
immunosuppressive stress, leading to increas-
The vaccination needs of each cat should be cannot be ed risk of disease by new infection or recrude-
evaluated individually and rationally, based scence. Each cat in a multi-cat environment
on health status, age, and possible, realistic applied to must have a vaccination plan that balances the
exposure to disease (Table 6). Owners and vet- every cat. Each protection of the individual with that of the
erinarians must work together to determine household population.1
the likelihood of the animal coming into animal must Cats entering boarding, breeding, foster,
contact with other animals that may spread or shelter situations have increased risk of
disease, acquiring parasites that may harbor a be evaluated disease exposure as well as systemic stress.
disease-causing agent, or living in an area and an Vaccination may be warranted prior to enter-
where a disease is known to be endemic or ing these environments when possible (see
very widespread.2 individualized Tables 2 and 3). Additionally, vaccination
Questions must be asked about the lifestyle intervals may need to be shortened depend-
of that specific cat as well as any other cats in
plan created ing upon these possible scenarios.1 As with
the household or potentially introduced into that will most multi-cat households, the vaccination plan for
the household. The travel, boarding, housing, the individual cat must be considered in rela-
and enrichment activities or excursions out- protect that tion to the entire population.
side of the home should also be considered.1 One vaccination plan or protocol cannot be
particular cat.
This risk assessment for exposure to disease applied to every cat. Each animal must be
should be done at least once a year. evaluated and an individualized plan created
The life stage of the cat must also be consid- that will most protect that particular cat. That
ered with respect to possibility of exposure to plan must be reassessed when changes in
disease and the health status of the animal. health and lifestyle occur, requiring client
Infectious diseases are more prevalent in kittens, education and compliance with at least yearly
and in general, kittens (younger than 6 months veterinary visits.38
old) are more susceptible to infection.1 Younger
cats also tend to behave more unpredictably and Feline patient populations
require more enrichment activities, which may
increase their opportunity for exposure.37 For the purpose of creating specific, individu‑
The health status of the individual cat, alized vaccination recommendations based on
including any previously documented risk of exposure, the Task Force has identified
adverse events to vaccines, also determines and defined the following feline populations
the vaccination recommendations. The based on their environment and lifestyle.
nutritional status, general health (i.e., any The guidelines begin by discussing pet cats
concurrent infections or other disease) and and then discuss a number of feline popula‑
the pregnancy status of females may change tions that are considered to be at relatively high

risk of infectious disease exposure; namely, Trap–neuter–return/trap–neuter–release

shelter cats, trap–neuter–return/trap–neuter– cats
release cats, cattery cats, and foster cats. These are community or feral cats of either sex
that live entirely separate from people and can-
Pet cats Clinicians not safely be handled. Trap–neuter–release/
Pet cats include any cat kept by human beings should trap–neuter–return cats may survive complete-
as a source of companionship and pleasure. ly independently of humans, but some semi-
Pet cats are further categorized by housing understand feral colonies receive support from individuals.
status (indoor, outdoor, or indoor–outdoor
cats) and number of cats in the household
when and why Cattery cats
(single-cat or larger multi-cat). Although these to perform These cats are maintained in commercial facil-
distinctions are important, the most signifi- ities; for example, breeding or boarding facili-
cant issue to consider regarding vaccination of antibody testing ties, and pet stores with a showcase model.
pet cats is the individual cat’s exposure risk
and exposure frequency to other cats and
and use this Foster cats
feline infectious diseases. Even indoor cats knowledge to Foster cats are kittens or adult cats temporari-
from single-cat households will inevitably be ly housed for rescue, rehabilitation, and
exposed to other feline infectious pathogens make evidence- rehoming purposes. The most important con-
in situations such as a veterinary clinic visit, based decisions sideration in a foster cat household is ensur-
contact with other cats entering the ing that the permanent population of the
premises, or exposure to contaminated prior to household is appropriately vaccinated to pro-
fomites introduced by human contact. Client vide protection from disease exposure origi-
education for owners of these patients should vaccination. nating with foster cats.
focus on risk of exposure to other cats rather
than on where the cat eats, sleeps, or spends Serology and diagnostics
most of its time.
For high-risk, multi-cat households, the The interpretation of an antibody test result
probability of infectious disease exposure and can be complex because antibody testing is
transmission is proportionate to the number used for many reasons. Depending on the
or density of cats on the premises.39 It is antibodies tested for, antibody testing can be
important to educate clients about the used for (1) diagnosis of infection, (2) identifi-
increased disease risks to this population of cation of previous exposure to pathogens
cats and to discuss increased owner responsi- (particularly in unvaccinated animals), and (3)
bility to ensure appropriate preventive health- assessment of immunity prior to or following
care initiatives associated with housing many vaccination (Table 7). Clinicians should
cats in a confined space. understand when and why to perform anti-
body testing and use this knowledge to make
Shelter cats evidence-based decisions prior to vaccination.
These are cats living for indeterminate peri- Hemagglutination inhibition (for FPV) and
ods in centers for relinquished or lost animals. serum neutralization (for FHV-1, FCV, and
3Table 7 Possible uses of in-clinic serology testing
Pathogen Usefulness of antibody testing

FPV Useful for assessment of immunity because presence of antibodies correlates strongly with protection.6,40 Result can be used to
decide whether to vaccinate (i.e., only vaccinate antibody-negative cats)
FHV-1 Not reliable for assessment of immunity.1,40 Effective immunity against FHV-1 requires both an antibody and cell-mediated immune
response. Result should not be used to decide whether to vaccinate
FCV Not reliable for assessment of immunity.1,40 Effective immunity against FCV requires both an antibody and cell-mediated immune
response. Result should not be used to decide whether to vaccinate
FeLV Useful for assessment of exposure and/or diagnosis of infection (in combination with other testing methodologies).41 Recently a rapid
in-clinic test kit to detect antibodies to FeLV transmembrane protein (p15E) was released in Europe. A positive p15E antibody result
cannot differentiate between exposure and infection. FeLV-vaccinated cats usually have low levels of antibodies to p15E.41 Results
from FeLV antigen testing (and not antibody testing) should be used to decide whether to vaccinate. Rapid in-clinic FeLV test kits
detect soluble p27 antigen in whole blood, serum, or plasma and are not affected by FeLV vaccination. The AAFP recommends testing
all cats for FeLV p27 antigen prior to initial vaccination. There is no proven benefit to vaccinating infected cats14,34,42
FIV Useful for diagnosis of infection.34 Between 2002 and 2015, an inactivated whole-virus vaccine was available in North America that
interferes with antibody results using some test kits.43,44 Additionally, cats may travel from locations where the vaccine is still in use to the
USA, Canada, and other countries where the vaccine is not available. FIV-vaccinated cats may test antibody positive for more than 7 years
after the last vaccination.45 Rapid in-clinic test kits able to differentiate between FIV-infected and FIV-vaccinated cats are available46
Rabies Vaccination against rabies is essential in regions where it is required by statute/law or where the virus is endemic and should follow
label recommendations. Serum neutralization results cannot be used to decide whether to vaccinate against rabies

rabies) are the reference standards to determine expiration date and manufacturer of the
the presence of effective antibody-mediated vaccine(s) given, date of administration, name
immunity. These test methodologies can only of the person administering the vaccine(s),
be performed in a laboratory setting using live and the site and route of the vaccine adminis-
cell cultures (i.e., they cannot be performed in tration. Adverse events should be recorded in
a practice using rapid patient-side test kits). a manner that will clearly alert all staff mem-
These diagnostic tests are predominantly bers during future visits.
research tools used in vaccine efficacy and
prevalence studies. Prevalence and types of adverse reactions
It is important when attempting to demon- Postvaccination adverse events in cats are con-
strate protective immunity in a patient using an sidered rare.49 In the most substantial survey to
in-clinic antibody test kit that the performance date, any adverse reactions were recorded for
of the kit be compared against the appropriate cats presented to Banfield Pet Hospitals in the
reference standard in order to demonstrate United States between 2002 and 2005.42 During
correlation with protective immunity. this period, more than 1.25 million doses of
The presence of anti-FPV antibodies corre- various vaccines were administered to nearly
lates strongly with protection (Table 7). 500,000 cats. Adverse reactions within 30 days
Currently, experts recommend antibody test- of vaccination were reported at a rate of 0.52%
ing for FPV to assess immunity and inform of cats vaccinated. The most commonly report-
decisions about whether to vaccinate.6,40 ed vaccine reactions are lethargy, anorexia, and
Rapid in-clinic test kits to detect antibodies to fever for a few days after vaccination, or local
FPV, FHV-1, and FCV are available to veteri- inflammation at the site of injection.42,50,51 In the
narians in North America and have been vali- Currently Banfield Pet Hospital population, the risk of an
dated in two different studies using the available feline adverse reaction was greatest in cats around
appropriate reference tests.47,48 Of concern, 1 year of age and/or increased as the total
however, was the occurrence of some anti- vaccines have volume of vaccine and number of vaccines
FPV antibody false-positive results in one administered concurrently increased.42
study, which in practice would lead to some an excellent
unprotected cats not being vaccinated.48 safety record. Hypersensitivity reactions
Although anaphylaxis (type I hypersensitivity
Adverse postvaccination reaction) is rare (approximately 1–5 per 10,000
reactions vaccinations),42,52 it may manifest as vomiting,
diarrhea, respiratory distress, facial or gener-
Although the administration of biological prod- alized pruritus, facial swelling, and col-
ucts is never entirely free of risk, currently avail- lapse.51,53,54 Where revaccination is considered
able feline vaccines have an excellent safety necessary in a cat that has experienced an
record. That said, the true prevalence of adverse allergic reaction, using a different vaccine
reactions is likely to be underestimated owing formulation and premedicating with an anti-
to underreporting by both veterinarians and histamine and glucocorticoid 20–30 minutes
owners.49 Therefore, it is important to report prior to vaccine administration is recom-
any known or suspected negative events mended, followed by close observation of the
associated with vaccination. In the United patient for several hours.42,53 Other forms of
States, veterinarians are requested to contact the hypersensitivity reactions (types II, III, and
manufacturer (Veterinary Technical Services) of IV) almost certainly also occur in cats after
the vaccine(s) considered to be involved. Veteri- vaccination, but these are rarely documented.
narians may also report known or suspected
adverse events directly to the U.S. Department Postvaccination monitoring
of Agriculture; the Center for Veterinary The Task Force recommends that veterinarians
Biologics of the U.S. Department of Agriculture’s and owners monitor the vaccination site for
Animal and Plant Health Inspection Service swelling or lumps using the “3-2-1” rule. Biopsy
can be contacted by the following means: of any mass present is warranted if it (1) remains
< Website: https://www.aphis.usda.gov/ present 3 months after vaccination, (2) is larger
aphis/ourfocus/animalhealth/veterinary- than 2 cm in diameter, or (3) is increasing in size
biologics/adverse-event-reporting/CT_ 1 month after vaccination.1,55 It is recommended
Vb_adverse_event. to obtain an incisional biopsy on any masses
< Mail: Send the report form to the Center meeting any of these criteria. Fine-needle aspi-
for Veterinary Biologics, 1920 Dayton Avenue, rates may not provide diagnostic cellular tissue,
PO Box 844, Ames, Iowa 50010, USA. whereas excisional biopsies rarely meet appro-
< Telephone: +1 (800) 752-6255. priate margins (5 cm in two fascial planes) as
At the time of vaccine administration, required in the case of injection-site sarcomas,
included in the patient’s permanent medical thus increasing the morbidity and mortality
record should be the name, serial number, risks associated with sarcoma invasion.

Update on feline injection-site < Tail vaccination has also been reported as
sarcomas well tolerated and elicited acceptable serolog-
ical responses to vaccination in the distal
FISSs, largely caused by vaccines (although limbs.57 To facilitate 5 cm margins in the case
other materials have been implicated), have of injection-site sarcoma, vaccinations must be
been recognized since 1991.56 Three decades administered in the distal tail, something that
later, much about them remains unknown. may not be practical for most clinicians.
Within the United States, FISS incidence esti- < Follow the 3-2-1 rule for postvaccination
mates, although low, have varied by at least swelling.1,55 Obtain incisional biopsies for
an order of magnitude, and worldwide FISS appropriate diagnosis.
incidence estimates vary by country depend- The 2013 AAFP Feline Vaccination Advisory
ing on the relative use of vaccine types (e.g., Panel Report included recommendations for
FeLV, rabies) and population susceptibility. specific vaccine antigens to be administered at
The Task Force makes the following obser- specific anatomical locations in the distal
vations regarding vaccination: limbs.1 This technique has helped facilitate the
< Neither vaccinating in the interscapular identification of the vaccine antigen used if a
space nor decreasing vaccine volume is sarcoma developed subsequently at the injec-
recommended. tion site. Since this technique has been widely
< Distal limb injection is recommended to adopted, these injection-site recommendations
facilitate amputation with 5 cm margins in two have also led to a shift in the site of tumor
fascial planes in the case of injection-site formation to the distal limbs, thus facilitating
sarcoma (Figure 1). potentially life-saving surgery for patients suf-
< More recently, ventral abdominal subcuta- fering from these invasive tumors.58 The 2020
neous injections have been used because of AAHA/AAFP Feline Vaccination Guidelines
the perceived relative ease of tumor removal Task Force recognizes and supports the value
without the need for amputation.2 However, of the 2013 recommendations and recognizes
the need to remove two fascial planes and that practitioners may, at times, need to use
5 cm margins would still necessitate aggres- medically appropriate discretion regarding the
sive tissue removal from the abdomen and anatomical location of vaccine administration.
abdominal cavity. Practitioners are strongly advised to keep com-
plete, accurate records for antigen administra-
tion site and route of vaccine administration.
The Task Force offers the following analysis
of current research about vaccine safety:
< Experimental studies of vaccine-induced
inflammation: These studies provide weak
evidence for detecting differential vaccination
effects on sarcoma incidence yet represent
progenitors of the “more vaccine-induced
inflammation leads to increased sarcoma risk”
conjecture. One immediate problem is that
it is unclear how to define inflammation in
the context of tumor induction. Macy and
Hendrick (1996) cite an unpublished study
that defined inflammation as “the size of
the local reaction.”59 Grosenbaugh et al.
(2004) interpreted it as the presence of
“injection-site reaction,” which could have
included “scab, crust, swelling, erosion,
ulceration, or pain at the injection site or
development of lameness.”28 Day et al. (2007)
used histopathological scoring that included
quantifying neutrophils, lymphocytes, and
macrophages (inflammatory phase of tissue
reaction); quantifying fibroblasts, collagen,
and granulation tissue (repair phase); and
assigning a “global severity score” based on
biopsy site reactivity and extension of
involvement of the tissue section.60 Because
the many manifestations of inflammation
in cats do not invariably lead to neoplasia, more
Figure 1 Vaccination sites: recommended injection sites in the distal limbs and tail. sensitive biomarkers such as DNA damage may
© iStock.com/GlobalP

Staff and client education

Worldwide FISS incidence estimates vary by country
The veterinarian’s role and responsibilities
depending on the relative use of vaccine types
< A veterinarian should assess every patient
(e.g., FeLV, rabies) and population susceptibility. regardless of appointment type (wellness,
acute care or follow-up visit) for current
vaccination status based on age and lifestyle.
one day be used to distinguish the potential for Informed by this assessment, an individual-
adjuvanted versus non-adjuvanted vaccines to ized patient vaccination plan should be devel-
induce tumors.61 But because none of the cats oped or modified and then discussed and
in the above studies developed sarcomas, such agreed upon in collaboration with the cat
experimental research does not have logical owner.
standing to infer relative vaccine safety. < In addition to overseeing the development
< Associational studies of diagnoses: In the of feline vaccination protocols, the veterinarian
past 10 years, two studies based on data from should provide staff education on the
pathology registries have provided contradic- following:
tory findings. Wilcock et al. (2012) found no – Zoonotic disease prevention.
decrease in the proportion of “post-vaccinal – Separate administration sites for each
sarcomas” in feline skin and subcutaneous vaccination (based on consistent vaccination
mass submissions from 1992 to 2010 in a site guidelines for that practice).
Canadian registry despite the introduction of – Potential life-threatening adverse events
a non-adjuvanted rabies vaccine in 2000.62 In (i.e., anaphylaxis) and minor adverse events
contrast, Graf et al. (2018) studied the propor- (i.e., localized swelling) following vaccination.
tion of feline biopsies that were fibrosarcomas – Vaccine reconstitution and handling (the
submitted to Swiss pathology laboratories AAFP recommends using vaccines within 30
between 2009 and 2014 and noted “a marked minutes of reconstitution).53
drop in the relative frequency of fibrosarcoma – Standard sharps safety procedures to
diagnoses after the introduction of a non- prevent accidental needle sticks.63
adjuvanted FeLV vaccine into the Swiss mar- The Centers for Disease Control and
ket” in 2007 (rabies vaccines are rarely used Prevention (CDC) online training module,
now in Switzerland).29 Such studies of diag- “You Call the Shots: Vaccine Storage and
nostic proportions are difficult to interpret. Handling,” is a useful resource for staff train-
Moreover, they are influenced not only by ing on vaccination.64 The practice should
disease incidence but also by factors related designate a person to be the primary vaccine
to differential cost and motivation for coordinator for the facility. This person will be
histopathologic diagnoses, which are subject responsible for ensuring all vaccines are
to change over time. Therefore, there are stored and handled correctly. A second staff
always competing explanations for findings. member to serve as an alternate in the absence
< Longitudinal studies of comparative inci- of the primary coordinator should be appoint-
dence: A study by Srivastav et al. (2012) is the ed (this is particularly important in case of
only one to perform a comparative (case- after-hours emergencies). Both coordinators
control) analysis of vaccine types in common should be fully trained in routine and emer-
use in the past 10 years.12 Unlike previous epi- gency policies and procedures.65
demiologic studies, it provides tenuous evi- The healthcare team, led by the veterinari-
dence that non-adjuvanted vaccines may be an, should emphasize and educate clients that
less likely to induce sarcomas than adjuvant- they are part of a team approach to vaccine
ed vaccines. However, the work suffers from management, requiring the entire staff’s
sample size limitations and bias concerns.30 understanding of zoonotic disease, core and
Although it arguably serves as an epidemio- non-core vaccines determined by the pet’s
logic-methods blueprint for future investiga- lifestyle, hospital policy, state law, client com-
tions, it is insufficient to justify a wholesale pliance, and adverse vaccination events.
recommendation for a single vaccine
formulation with as yet unforeseen Credentialed veterinary technician
consequences on population immuni- or veterinary assistant roles and
ty. The Task Force believes that there responsibilities
is currently insufficient research to FREQUENTLY ASKED A veterinary technician or assistant often
justify recommending a single vac- QUESTIONS assumes the role of designated vaccine coor-
cine type. Since injection-site sarco- A summary of frequently asked dinator, assisting in vaccination storage and
questions is available online at
mas are a risk, the Task Force aaha.org/felinevaccination and
inventory management. AAHA guidelines on
recommends vaccination in the lower catvets.com/vaccination vaccine storage and handling, and the CDC
distal limbs to facilitate clean margins Vaccine Storage and Handling Toolkit are use-
if surgical amputation is required. ful resources for this purpose.64,65 The vaccine

coordinator is often responsible for reconsti- vaccinations in advance as directed by the pre-
tution of vaccines and administration of scribing veterinarian. Non-clinical staff should
vaccinations as directed by the attending understand the potential life-threatening
veterinarian in compliance with state law.66 and minor adverse events that can occur fol-
This individual is also often given responsibil- lowing vaccination that require veterinary
ity for implementing feline-friendly handling assistance.
techniques in the hospital setting to minimize
stress during examinations and vaccine Client education
administration67 and for maintaining effective Pet owner clients are an essential member of a
client education and follow-up, including cat’s healthcare team. Although clients can be
verbal and written instructions on potential instrumental in helping improve healthcare
adverse events after vaccine administration for their cats, the Task Force recom-
and disease prevention. mends that vaccination be performed
by a veterinarian. Vaccination is a
Roles and responsibilities of reception medical procedure. Vaccines are
and other client-service personnel available through sources other
The reception staff is typically charged with ADDITIONAL CLIENT than a veterinarian, but they
maintaining patient files with vaccination EDUCATION RESOURCES may not protect a cat against
information, including date administered, To help educate clients about vaccine and disease unless properly stored,
general health issues, both AAHA and the
along with the production lot serial number handled, and administered. The
AAFP have handouts available to members
and expiration date of the vaccine. and non-members. Additionally, more principles of feline vaccination
Reception personnel are also responsible for extensive information is available at outlined in the box below repre-
contacting clients and scheduling follow-up aaha.org/felinevaccination and sent a basic client education
appointments for booster series and yearly catvets.com/vaccination overview for cat owners.
tVa c c i n a t i o n t a l k i n g p o i n t s f o r c l i e n t s
Vaccines help protect against specific infectious Veterinarian-administered vaccination is particu-
diseases. They stimulate the body’s immune sys- larly important with respect to rabies. Rabies is a
tem to recognize and fight an infection. Without fatal but preventable disease that can be spread to
vaccination, many cats would become seriously ill humans by contact with saliva from an infected
or die from preventable diseases. Some infections individual. If an unvaccinated cat is scratched or
are more difficult to prevent using vaccination bitten by a wild animal, or if it bites a person, it
than others. For example, vaccination is very should be quarantined or euthanized. In many US
effective against feline panleukopenia infection states, it is against the law for anyone other than a
but does not entirely protect against respiratory licensed veterinarian to administer a rabies vac-
virus infections. However, cats vaccinated against cine. Rabies vaccination of cats is required by law
respiratory tract infections generally have milder in many but not all states. Ontario is the only
illness and are far less likely to die Canadian province that requires
from their disease. A veterinarian rabies vaccination of cats. Even in
A veterinarian is the best person areas where it is not required, feline
to evaluate a cat’s individual vacci- is the best rabies vaccination is still recommend-
nation needs. Many factors need to ed (i.e., it is a core vaccine).
be taken into consideration when
person to Severe vaccine reactions are rare.
deciding how often and for what evaluate a cat’s Veterinarians should convey the
diseases a feline patient needs to appropriate risk–benefit analysis of
be vaccinated. These considera- individual any vaccination. Cats may experi-
tions include health status, age, and ence mild, short-lived reactions
lifestyle of the cat; a vaccine’s dura-
vaccination (malaise) such as poor appetite,
tion of immunity; what diseases are needs. lethargy, and fever that will resolve
prevalent in the area; and the sever- without treatment. Clients should
ity of endemic diseases. Even cats seek immediate veterinary attention
living exclusively indoors require if their cat begins vomiting or
regular vaccination because they scratching, develops bumps (hives)
still may be exposed to diseases in or facial swelling, or has difficulty
many circumstances, such as when breathing within a few hours of being
traveling or boarding, visiting a veterinary practice, vaccinated. The client and veterinary practice
interacting with other cats, or through viruses team have the same goal: to provide the best
carried on the pet owner’s hands or clothing. possible care for the pet.

SUMMARY points
< Vaccination protocols for cats should consist of recommended core vaccines and discretionary non-core vaccines
as defined and listed in the guidelines. Vaccines in the latter category are given based on a risk–benefit assessment.
Risk is determined by the patient’s life stage, lifestyle, clinical history, and health status and by environmental and
epidemiologic risk factors.
< Although feline vaccination is universally practiced by primary care companion animal practices, there is no single
protocol suitable for all feline patients. Rather, vaccination of cats should be patient-specific and guided by an individual
risk–benefit assessment using the criteria listed in the guidelines.
< In the case of some vaccines, practitioners have a choice of different types of antigens, including those that are
inactivated, attenuated, and in recombinant form. The patient’s clinical and vaccination status, such as the possible
presence of maternally derived immunity or a history of adverse postvaccination reactions, are factors that may
influence the choice of vaccine type.
< Although most feline patients are household pets, practitioners should anticipate situations in which higher-risk cats
are presented for vaccination, including those from shelter, cattery, feral, or foster care origins.
< Adverse postvaccination reactions unavoidably occur in a small percentage of cats. Because of their neoplastic
etiology, FISSs continue to be the most serious, if infrequent, vaccine-associated adverse event. Detection of patterns
in FISS incidence remains elusive, and their occurrence continues to be idiosyncratic. Advising clients in advance of
the possibility of hypersensitivity or other reactions will help minimize their concerns.
< All members of the practice team, including clinical and non-clinical personnel, should have a well-informed
understanding of the importance of vaccination of feline patients and be able to advise clients of the practice’s
approach to an individualized vaccination plan.
< The vaccination visit is an ideal time for a client education dialog in which the clinical staff has an
opportunity to discuss the role of vaccination as an essential component of preventive healthcare
tailored to the individual patient.
Acknowledgments Informed consent
The Task Force gratefully acknowledges the contribution of This work did not involve the use of animals and, therefore,
Mark Dana of Scientific Communications Services, LLC, and the informed consent was not required. For any animals individually
Kanara Consulting Group, LLC, in the preparation of the identifiable within this publication, informed consent (either
guidelines manuscript. verbal or written) for their use in the publication was obtained
from the people involved.
Conflict of interest
References
Amy ES Stone has received speaking fees from Boehringer
Ingelheim Animal Health USA Inc. Jane Sykes receives honoraria 1 Scherk MA, Ford RB, Gaskell RM, et al. 2013 AAFP Feline
and research funding from Boehringer Ingelheim Animal Health Vaccination Advisory Panel Report. J Feline Med Surg 2013;
USA Inc., Elanco Animal Health, IDEXX Laboratories Inc., and 15: 785–808.
Merck Animal Health. Ernest P Petersen was a stockholder of 2 Day MJ, Horzinek MC, Schultz RD, et al. WSAVA guidelines
Phoenix Central Laboratory prior to its sale to Zoetis Petcare for the vaccination of dogs and cats. J Small Anim Pract 2016;
(after these guidelines were written) but was not employed at the 57: E1–45.
lab nor on the Board of Governors, and was not involved in the 3 Volk JO, Felsted KE, Thomas JG, et al. Executive summary of
sale. The other members of the Task Force have no conflicts of the Bayer veterinary care usage study. J Am Vet Med Assoc
interest to declare. 211; 238: 1275–1282.
4 Casal ML, Jezyk PF and Giger U. Transfer of colostral anti-
Funding bodies from queens to their kittens. Am J Vet Res 1996; 57:
1653–1658.
Boehringer Ingelheim Animal Health USA Inc., Elanco Animal 5 DiGangi BA, Levy JK, Griffin B, et al. Effects of maternally-
Health, Merck Animal Health, and Zoetis Petcare supported the derived antibodies on serologic responses to vaccination in
development of the 2020 AAHA/AAFP Feline Vaccination kittens. J Feline Med Surg 2012; 14: 118–123.
Guidelines and resources through an educational grant to AAHA. 6 DiGangi BA, Levy JK, Griffin B, et al. Prevalence of serum
antibody titers against feline panleukopenia virus, feline
Ethical approval herpesvirus 1, and feline calicivirus in cats entering a
Florida animal shelter. J Am Vet Med Assoc 2012; 241:
This work did not involve the use of animals and, therefore, ethical 1320–1325.
approval was not necessarily required. 7 Jakel V, Cussler K, Hanschmann KM, et al. Vaccination

against feline panleukopenia: implications from a field vaccinated cats when challenged with a homologous feline
study in kittens. BMC Vet Res 2012; 8: 62. calicivirus strain associated with virulent systemic disease.
8 American Animal Hospital Association Canine Vaccination J Feline Med Surg 2010; 12: 129–137.
Task Force; Welborn LV, DeVries JG, et al. 2011 AAHA canine 24 Bradley A, Kinyon J, Frana T, et al. Efficacy of intranasal
vaccination guidelines. J Am Anim Hosp Assoc 2011; 47: 1–42. administration of a modified live feline herpesvirus 1
9 Brun A, Chappuis G, Precausta P, et al. Immunisation against and feline calicivirus vaccine against disease caused
panleukopenia: early development of immunity. Comp by Bordetella bronchiseptica after experimental challenge.
Immunol Microbiol Infect Dis 1979; 1: 335–339. J Vet Intern Med 2012; 26: 1121–1125.
10 Larson LJ, Newbury S and Schultz RD. Canine and feline 25 Schultz RD. A commentary on parvovirus vaccination. J Feline
vaccinations and immunology. In: Miller L and Hurley K Med Surg 2009; 11: 163–164.
(eds). Infectious disease management in animal shelters. 26 Wilson S, Greenslade J, Saunders G, et al. Difficulties in
Ames, IA: Wiley-Blackwell, 2009, pp 61–82. demonstrating long term immunity in FeLV vaccinated cats
11 Larson LJ and Schultz RD. Effect of vaccination with recom- due to increasing age-related resistance to infection.
binant canine distemper virus vaccine immediately before BMC Vet Res 2012; 8: 125. DOI: 10.1186/1746-6148-8-125.
exposure under shelter-like conditions. Vet Ther 2006; 7: 27 Jirjis FF, Davis T, Lane J, et al. Protection against feline
113–118. leukemia virus challenge for at least two years after vacci-
12 Srivastav A, Kass PH, McGill LD, et al. Comparative vaccine- nation with an inactivated feline leukemia virus vaccine.
specific and other injectable-specific risks of injection-site Vet Ther 2010: 11: E1–6.
sarcomas in cats. J Am Vet Med Assoc 2012; 241: 595–602. 28 Grosenbaugh DA, Leard T, Pardo MC, et al. Comparison of
13 Patel M, Carritt K, Lane J, et al. Comparative efficacy of the safety and efficacy of a recombinant feline leukemia
feline leukemia virus (FeLV) inactivated whole-virus vac- virus (FeLV) vaccine delivered transdermally and an inacti-
cine and canarypox virus-vectored vaccine during virulent vated FeLV vaccine delivered subcutaneously. Vet Ther 2004;
FeLV challenge and immunosuppression. Clin Vaccine 5: 258–262.
Immunol 2015; 22: 798–805. 29 Graf R, Guscetti F, Welle M, et al. Feline injection site sarco-
14 Torres AN, O’Halloran KP, Larson LJ, et al. Feline leukemia mas: data from Switzerland 2009–2014. J Comp Pathol 2018;
virus immunity induced by whole inactivated virus vacci- 163: 1–5.
nation. Vet Immunol Immunopathol 2010; 134: 122–131. 30 Kass PH. Prevention of feline injection-site sarcomas: is
15 Sharp NJ, Davis BJ, Guy JS, et al. Hydranencephaly and cere- there a scientific foundation for vaccine recommendations
bellar hypoplasia in two kittens attributed to intrauterine at this time? Vet Clin North Am Small Anim Pract 2018; 48:
parvovirus infection. J Comp Pathol 1999; 121: 39–53. 301–306.
16 Disease Information Fact Sheet: Feline Panleukopenia. J Feline 31 Klingborg DJ, Hustead DR, Curry-Galvin EA, et al. AVMA
Med Surg 2013; 15: Supplementary File. This Disease Council on Biologic and Therapeutic Agents’ report on cat
Information Fact Sheet accompanies the 2013 AAFP Feline and dog vaccines. J Am Vet Med Assoc 2002; 221: 1401–1407.
Vaccination Advisory Panel Report published in J Feline Med 32 Starr RM. Reaction rate in cats vaccinated with a new
Surg 2013; 15: 785–808. controlled-titer feline panleukopenia rhinotracheitis-
17 Buonavoglia C, Marsiolio F, Tempesta M, et al. Use of a feline calicivirus-Chlamydia psittaci vaccine. Cornell Vet 1993; 83:
panleukopenia modified live virus vaccine in cats in the 311–323.
primary-stage of feline immunodeficiency virus infection. 33 Disease Information Fact Sheet: Feline Infectious Peritonitis.
Zentralbl Veterinarmed B 1993; 40: 343–346. J Feline Med Surg 2013; 15: Supplementary File. This Disease
18 Reubel GH, Dean GA, George JW, et al. Effects of incidental Information Fact Sheet accompanies the 2013 AAFP Feline
infections and immune activation on disease progression in Vaccination Advisory Panel Report published in J Feline Med
experimentally feline immunodeficiency virus-infected Surg 2013; 15: 785–808.
cats. J Acquir Immune Defic Syndr 1994; 7: 1003–1015. 34 Little S, Levy J, Hartmann K, et al. 2020 AAFP feline retro-
19 Chalmers WS, Truyen U, Greenwood NM, et al. Efficacy of virus testing and management guidelines. J Feline Med Surg
feline panleucopenia vaccine to prevent infection with an 2020; 22: 5–30.
isolate of CPV2b obtained from a cat. Vet Microbiol 1999; 69: 35 Fenimore A, Carter K, Fankhauser J, et al. Evaluation of
41–45. intranasal vaccine administration and high-dose interferon-
20 Nakamura K, Ikeda Y, Miyazawa T, et al. Characterisation of alpha2b therapy for treatment of chronic upper respiratory
cross-reactivity of virus neutralising antibodies induced by tract infections in shelter cats. J Feline Med Surg 2016; 18: 603–611.
feline panleukopenia virus and canine parvoviruses. Res Vet 36 Helfer-Hungerbuehler AK, Spiri AM, Riond B, et al. No
Sci 2001; 71: 219–222. benefit of therapeutic vaccination in clinically healthy cats
21 Lappin MR. Feline panleukopenia virus, feline herpesvirus- persistently infected with feline leukemia virus. Vaccine
1 and feline calicivirus antibody responses in seronegative 2015; 33: 1578–1585.
specific pathogen-free kittens after parenteral administra- 37 Vogt AH, Rodan I, Brown M, et al. AAFP–AAHA feline life
tion of an inactivated FVRCP vaccine or a modified live stage guidelines. J Am Anim Hosp Assoc 2010; 46: 70–85.
FVRCP vaccine. J Feline Med Surg 2012; 14: 161–164. 38 Adams CL and Kurtz S. Skills for communicating in
22 Truyen U, Addie D, Belák S, et al. Feline panleukopenia. veterinary medicine. Parsippany, NJ: Dewpoint Publishing,
ABCD guidelines on prevention and management. J Feline 2017, p 112.
Med Surg 2009; 11: 538–546. 39 Kass PH and Dent TH. The epidemiology of feline infec-
23 Huang C, Hess J, Gill M, et al. A dual-strain feline calicivirus tious peritonitis in catteries. Feline Pract 1995; 23: 27–32.
vaccine stimulates broader cross-neutralization antibodies 40 Lappin MR, Andrews J, Simpson D, et al. Use of serologic
than a single-strain vaccine and lessens clinical signs in tests to predict resistance to feline herpesvirus 1, feline cali-

civirus, and feline parvovirus infection in cats. J Am Vet Med 53 Richards JR, Elston TH, Ford RB, et al. The 2006 American
Assoc 2002; 220: 38–42. Association of Feline Practitioners Feline Vaccine Advisory
41 Boenzli E, Hadorn M, Hartnack S, et al. Detection of anti- Panel Report. J Am Vet Med Assoc 2006; 229: 1405–1441.
bodies to the feline leukemia virus (FeLV) transmembrane 54 Davis-Wurzler GM. Current vaccination strategies in pup-
protein p15e: an alternative approach for serological FeLV pies and kittens. Vet Clin North Am Small Anim Pract 2006; 36:
detection based on antibodies to p15e. J Clin Microbiol 2014; 607–640, vii.
52: 2046–2052. 55 Vaccine-Associated Feline Sarcoma Task Force. The current
42 Moore GE, DeSantis-Kerr AC, Guptill LF, et al. Adverse understanding and management of vaccine-associated
events after vaccine administration in cats: 2560 cases sarcomas in cats. J Am Vet Med Assoc 2005; 226: 1821–1842.
(2002–2005). Vet Clin North Am Small Anim Pract 2010; 40: 56 Hendrick MJ and Goldschmidt MH. Do injection site reac-
393–407. tions induce fibrosarcomas in cats? J Am Vet Med Assoc 1991;
43 Uhl EW, Heaton-Jones TG, Pu R, et al. FIV vaccine 199: 968.
development and its importance to veterinary and human 57 Hendricks CG, Levy JK, Tucker SJ, et al. Tail vaccination in
medicine: FIV vaccine 2002 update and review. Vet Immunol cats: a pilot study. J Feline Med Surg 2014; 16: 275–280.
Immunopathol 2002; 90: 113–132. 58 Shaw SC, Kent MS, Gordon IK, et al. Temporal changes in
44 Yamamoto JK, Sanou MP, Abbott JR, et al. Feline immuno- characteristics of injection-site sarcomas in cats: 392 cases
deficiency virus model for designing HIV/AIDS vaccines. (1990–2006). J Am Vet Med Assoc 2009; 234: 376–380.
Curr HIV Res 2010; 8: 14–25. 59 Macy DW and Hendrick MJ. The potential role of inflamma-
45 Westman ME, Malik R, Hall E, et al. Determining the feline tion in the development of postvaccinal sarcomas in cats.
immunodeficiency virus (FIV) status of FIV-vaccinated cats Vet Clin North Am Small Anim Pract 1996; 26: 103–107.
using point-of-care antibody kits. Comp Immunol Microbiol 60 Day MD, Schoon HA, Magnol JP, et al. A kinetic study of
Infect Dis 2015; 42: 43–52. histopathological changes in the subcutis of cats injected
46 Levy JK, Crawford P and Tucker SJ. Performance of 4 point- with nonadjuvanted and adjuvanted multi-component
of-care screening tests for feline leukemia virus and feline vaccines. Vaccine 2007; 25: 4073–4084.
immunodeficiency virus. J Vet Intern Med 2017; 31: 521–526. 61 Kang S, Southard T and Hume KR. DNA damage is a feature
47 DiGangi BA, Gray LK, Levy JK, et al. Detection of protective of feline injection-site sarcoma. Vet Comp Oncol 2016; 15:
antibody titers against feline panleukopenia virus, feline 518–524.
herpesvirus-1, and feline calicivirus in shelter cats using a 62 Wilcock B, Wilcock A and Bottoms K. Feline postvaccinal
point-of-care ELISA. J Feline Med Surg 2011; 13: 912–918. sarcoma: 20 years later. Can Vet J 2012; 53: 430–434.
48 Mende K, Stuetzer B, Truyen U, et al. Evaluation of an in- 63 Weese JS and Jack DC. Needlestick injuries in veterinary
house dot enzyme-linked immunosorbent assay to detect medicine. Can Vet J 2008; 49: 780–784.
antibodies against feline panleukopenia virus. J Feline Med 64 Centers for Disease Control and Prevention. CDC Vaccine
Surg 2014; 16: 805–811. Storage and Handling Toolkit. Available at: https://
49 Gaskell R, Gettinby G, Graham S, et al. Veterinary Products www.cdc.gov/vaccines/hcp/admin/storage/toolkit/
Committee working group report on feline and canine storage-handling-toolkit.pdf (accessed September 24, 2019).
vaccination. Vet Rec 2002; 150: 126–134. 65 Ford RB, Larson LJ, McClure KD, et al. 2017 AAHA canine vac-
50 Day MJ. Vaccine side effects: fact and fiction. Vet Microbiol cination guidelines. J Am Anim Hosp Assoc 2017; 53: 243–251.
2006; 117: 51–58. 66 American Veterinary Medical Association. Rabies Vaccination
51 Moore GE and HogenEsch H. Adverse vaccinal events in State Law Summary. Available at: https://www.avma.org/
dogs and cats. Vet Clin North Am Small Anim Pract 2010; 40: Advocacy/StateAndLocal/Documents/Rabies-state-law-
393–407. chart.pdf (accessed September 24, 2019).
52 Clark N, Kushner NN, Barrett CB, et al. Efficacy and safety field 67 Rodan I, Sundahl E, Carney H, et al. AAHA and ISFM feline-
trials of a recombinant DNA vaccine against feline leukemia friendly handling guidelines. J Feline Med Surg 2011; 13:
virus infection. J Am Vet Med Assoc 1991; 199: 1433–1443. 364–375.
Available online at jfms.com and catvets.com/vaccination

Article reuse guidelines: sagepub.co.uk/journals-permissions

2020 AAHAAAFP Feline Vaccination Guidelines

Uploaded by

Copyright:

Available Formats

2020 AAHAAAFP Feline Vaccination Guidelines

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

2020 AAHAAAFP Feline Vaccination Guidelines

Uploaded by

Copyright:

Available Formats

813_830_AAHA_AAFP Feline Vaccination Guidelines_3.8.2020.

qxp_FAB 03/08/2020 13:13 Page 813

Journal of Feline Medicine and Surgery (2020) 22, 813–830

2020 AAHA/AAFP Feline

S P E C I A L A R t i c l e / 2020 AAHA/AAFP feline vaccination guidelines

the Vaccination of Dogs and Cats”.1,2 Both of Vaccination principles

814 JFMS CLINICAL PRACTICE

S P E C I A L A R t i c l e / 2020 AAHA/AAFP feline vaccination guidelines

Table 1 Types of feline vaccines and their attributes

Attributes Inactivated Attenuated live Recombinant

Vaccine organism- Not possible Possible, but uncommon, Not possible

JFMS CLINICAL PRACTICE 815

S P E C I A L A R t i c l e / 2020 AAHA/AAFP feline vaccination guidelines

816 JFMS CLINICAL PRACTICE

S P E C I A L A R t i c l e / 2020 AAHA/AAFP feline vaccination guidelines

Table 2 Core vaccines for pet cats (continued on page 818)

<16 Weeks of >16 Weeks of

when presented for initial vaccination may

< Although mucosal vaccines are not

JFMS CLINICAL PRACTICE 817

S P E C I A L A R t i c l e / 2020 AAHA/AAFP feline vaccination guidelines

<16 Weeks of >16 Weeks of

early as 8 weeks revaccination:* < Considered a non-core vaccine for low-risk

vaccines, canarypox vectors offer a more rapid

818 JFMS CLINICAL PRACTICE

S P E C I A L A R t i c l e / 2020 AAHA/AAFP feline vaccination guidelines

3Table 3 Core vaccines for shelter-housed cats

<20 Weeks of >20 Weeks of

intake or where intake or where for cerebellar hypoplasia15,16

Administration instructions Clinically relevant comments for administration

JFMS CLINICAL PRACTICE 819

S P E C I A L A R t i c l e / 2020 AAHA/AAFP feline vaccination guidelines

3Table 4 Non-core vaccines for pet cats

Clinically relevant comments for

label instructions < Provides incomplete protection optional

risk of adverse effects (lethargy, limb soreness,

To facilitate vaccine selection, vaccines for significance or that respond readily to

Table 5 Not generally recommended vaccines for pet cats

recommended. seropositive before the age of recommended

820 JFMS CLINICAL PRACTICE

S P E C I A L A R t i c l e / 2020 AAHA/AAFP feline vaccination guidelines

JFMS CLINICAL PRACTICE 821

S P E C I A L A R t i c l e / 2020 AAHA/AAFP feline vaccination guidelines

nary clinic for a wellness examination. In 3Table 6

Infectious agents the type and schedule of vaccination for that

822 JFMS CLINICAL PRACTICE

S P E C I A L A R t i c l e / 2020 AAHA/AAFP feline vaccination guidelines

risk of infectious disease exposure; namely, Trap–neuter–return/trap–neuter–release

3Table 7 Possible uses of in-clinic serology testing

Pathogen Usefulness of antibody testing

JFMS CLINICAL PRACTICE 823

S P E C I A L A R t i c l e / 2020 AAHA/AAFP feline vaccination guidelines

824 JFMS CLINICAL PRACTICE

S P E C I A L A R t i c l e / 2020 AAHA/AAFP feline vaccination guidelines

JFMS CLINICAL PRACTICE 825

S P E C I A L A R t i c l e / 2020 AAHA/AAFP feline vaccination guidelines

Staff and client education

826 JFMS CLINICAL PRACTICE

S P E C I A L A R t i c l e / 2020 AAHA/AAFP feline vaccination guidelines

JFMS CLINICAL PRACTICE 827